INTRODUCTION
============

Chikungunya virus (CHIK-V) was first identified in 1952, in Tanzania[@B1]. Later, since the 1960s, outbreaks have occurred in Asia and Africa[@B1]. Chikungunya fever (CHIK-F) was seldomly reported during the 20^th^ century. However, in 1999, there was an outbreak in the Democratic Republic of Congo, and in 2005 outbreaks occurred in the Indian ocean islands subsequently spreading to some Asian countries, Europe, and the Americas^1^. Recently, it was added to the list of neglected tropical diseases[@B2].

CHIK-F is an acute febrile illness commonly presenting with acute onset of pyrexia along with inflammatory arthralgia and arthritis, sometimes with severe pain, most frequently in the extremities (wrists, ankles, and phalanges)[@B3]. Diagnostic laboratory investigations include serological testing and polymerase chain reaction, sometimes performed in cerebral spinal fluid[@B3]. Some guidelines or reviews are indicating that CHIK-F may be asymptomatic in up to 13% of all cases, with rare atypical presentations occurring in approximately 1% of all cases[@B3] ^,^ [@B4].

CHIK-F lethality is believed to be as low as 0,1%, but the disease can be easily mistaken with Dengue fever or other acute febrile illness[@B5] ^,^ [@B6], and its mortality may be underestimated during outbreaks[@B6]. Clinical alarms that would justify hospitalization are sometimes unclear in guidelines but may include severe manifestations or atypical findings, such as intense pain, bleeding, dehydration, thrombosis or decompensation of previous clinical conditions[@B3] ^,^ [@B5]. Additionally, it is not clear from reference documents or current guidelines if clinical events preceding death are primarily attributable to CHIK-V, or if these events are exacerbations of previous conditions, or how often they occur. It is also unclear which CHIK-F patients are at higher risk of death. Therefore, this study aimed to systematically review the medical literature regarding CHIK-F deaths and identify clinical features that precede death among CHIK-F patients. This will uncover features that could be used severity alerts, guiding the need for hospitalization or intensive care.

METHODS
=======

This review's protocol was registered at the international prospective register of systematic reviews (Prospero) and can be found at http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017056692.

The population of interest for this review was defined as any case of laboratory-confirmed CHIK-V infection, for example by serological or DNA amplification methods. Additionally, the report contained at least one death attributable to CHIK-F. Any observational or interventional study design was accepted. There was no period, language, or publication status restriction, and symposium, congress summary, or posters were all accepted. Reports with data regarding exclusively pregnant patients or CHIK-V vertical transmission were of no interest to this review.

The search was based on two strategies. First, the search of remote electronic databases, followed by the manual search of references at the bibliography of the full papers retrieved.

The remote database searches were performed using PubMed, LILACS, Scopus, Embase, and Web of Science. The first searches were performed on February 23^rd^, 2017 and the last updated search was done on December 18^th^, 2019. The search strategies were as follow: PubMed - chikungunya AND (death\* OR dead OR died OR mortality OR lethality OR fatal\*) AND (severe OR \"intensive care\" OR ICU OR clinic\* OR myocardi\* OR hepatitis OR enceplhalopath\* OR meningit\* OR sepsis OR septic); Web of Science - TS=(chikungunya) AND TS=(death\* OR dead OR died OR mortality OR lethality OR fatal\*) AND TS=(severe OR \"intensive care\" OR ICU OR clinic\* OR myocardi\* OR hepatitis OR enceplhalopath\* OR meningit\* OR sepsis OR septic); Scopus - chikungunya AND (death\* OR dead OR died OR mortality OR lethality OR fatal\*) AND (severe OR \"intensive care\" OR ICU OR clinic\* OR myocardi\* OR hepatitis OR enceplhalopath\* OR meningit\* OR sepsis OR septic); Embase - chikungunya AND (death\* OR dead OR died OR mortality OR lethality OR fatal\*) AND (severe OR \"intensive care\" OR ICU OR clinic\* OR myocardi\* OR hepatitis OR enceplhalopath\* OR meningit\* OR sepsis OR septic); Lilacs - chikungunya AND (morte\* OR mortalidade OR letalidade OR morre\* OR death\* OR dead OR died OR mortality OR lethality OR fatal\*) AND (sever\* OR \"intensive care\" OR \"terapia intensiva\" OR ICU OR UTI OR clinic\* OR myocardi\* OR miocardio\* OR hepatitis OR hepatite OR enceplhalopath\* OR encefalopatia OR meningit\* OR sepsis OR septic).

All four authors reviewed the abstracts and retrieved data from the full text. Each reviewer performed the classification and data extraction independently. The abstracts were downloaded to Zotero® reference manager. After the first screening, full reports files were captured, and then the extracted data were recorded using the RedCap® software. At each round of classification, a third reviewer voted on how to solve disagreements.

For data collection, a specific form was designed and piloted several times until an agreement was reached by the reviewers. The forms contained study characteristics such as publication type, population characteristics such as the country where research occurred, special characteristics such as critically ill or with a neurologic manifestation, period of inclusion, comorbidities, and organic dysfunction. Regarding organic dysfunction, the following definitions were adapted from the SOFA score (Sepsis-related Organ Failure)[@B7]: bilirubin \> 1.2mg/dl or changes in INR due to liver dysfunction; the need for orotracheal tube or non-invasive ventilation for respiratory dysfunction; the need for blood components transfusion or platelets count \< 150.000/ mm^3^ for hematologic dysfunction; the need for vasoactive agents, or mean arterial pressure \< 70 or shock for cardiovascular dysfunction; the need for dialysis or creatinine \> 1.2mg/dL for renal dysfunction; seizures, abnormal behavior, abnormal motor functions, abnormal sensorial functions, or Glasgow score \< 15 for neurologic dysfunction.

The critical appraisal for all reports included was performed using the checklist for case series of the Joanna Briggs Institute - University of Adelaide available at (http://joannabriggs.org/research/critical-appraisal-tools.html)[@B8]. The analysis plan is based on narrative and descriptive analysis, and frequencies of events of interest. The main subgroups of interest are the elderly and those with comorbidities. The critical appraisal was used only for overall quality evaluation.

RESULTS
=======

After performing the remote database search, 3746 abstracts were retrieved. After the removal of replicated abstracts and applying the eligibility criteria, a total of 57 reports were analyzed[@B9] ^-^ [@B64]. ([Figure 1](#f1){ref-type="fig"}) The majority of exclusions were due to the absence of death reports in the original study sample. The included reports were mostly case series (45.6%) followed by case reports (28.1%), and observational follow-up studies (26.3%). ([Table 1](#t1){ref-type="table"}) The review included 2140 deaths. ([Table 1](#t1){ref-type="table"}) The overall death rate ranged from 0.1% to 100%, however, considering only the observational follow-up studies, the median non-weighted death rate was 3.1%, ranging from 0.1% to 36.7% in the general population, and 36.7% ranging from 27.7% to 48.8% among critically ill subjects.

FIGURE 1:Inclusion and exclusion flowchart.

TABLE 1:Study description and Chikungunya death rates.StudyStudy typeCountryPeriodSpecial populationDays to death (central tendency)Number of DeathsChikungunya casesDeath rate (%)Sarkar - 1967Observational with follow-upIndia1963-1965General population-2643.1Ramful - 2007Case seriesFrance2005-2006Neonatal-1382.6Rampal - 2007Case seriesIndia2006-2006Neurologic2862030Renault - 2007Case seriesFrance2005-2006General population-203160501.3Ernould - 2008Case seriesFrance2006-2006Pediatric-2653.1Ganesan - 2008Case reportIndia2008-2008Neurologic-1250Lemant - 2008Case seriesFrance2005-2006Critically ill5163348.5Robin - 2008Case seriesFrance2006-2006Pediatric with neurological52306.7Economopoulou - 2009Case seriesFrance2005-2006Atypical manifestations-658787.4Suryawanshi - 2009Case seriesIndia2006-2006General population-3873.4Tandale - 2009Observational with follow-upIndia2006-2006Hospitalized-269028.9Tournebize - 2009Case seriesFrance2005-2006Neurologic-2267.7Chua - 2010Case reportMalaysia2010-2010Pediatric511100Kee - 2010Case reportSingapure2008-2008Immunocompromised1501250Sam - 2010Case reportMalaysia2008-2008Cardiologic511100Gaüzère - 2011Observational with follow-upFrance2005-2006Critically ill-214348.8Gurav - 2012Case seriesIndia2011-2011General population-31791.7Hertz - 2012Observational with follow-upTanzania2007-2008Hospitalized-5559.1Garcia - 2014Case reportPhilippines2014-2014General population-22100Bhooshan - 2015Observational with follow-upIndia2010-2010Hospitalized-5796.3Hoz - 2015Case reportColombia2014-2014General population533100Shaikh - 2015Case reportIndia2014-2014Neurologic811100Sharp - 2015Case seriesPuerto Rico2014-2014Post mortem62828100Thiery - 2015Observational with follow-upFrance2014-2014Critically ill-186527.7Torres - 2015Case seriesVenezuela2014-2015Critically ill63475Viasus - 2015Case reportColombia2015-2015Geriatric511100Betancur - 2016Case reportColombiaNA-NACritically ill811100Carta - 2016Observational with follow-upVenezuelaNA-NAGeneral population-32871Crosby - 2016Case seriesFrance2014-2014Critically ill-186527.7Gérardin - 2016Observational with follow-upFrance2005-2009Neurologic-75712.3López - 2016Observational with follow-upPuerto Rico2014-2014General population-214690.1Méndez-Domínguez - 2016Case reportMexico2015-2015Pediatric411100Mercado - 2016Case seriesColombia2014-2015Dengue co-infection377100Perti - 2016Observational with follow-upUSA2014-2014General population-61803.3Rollé - 2016Observational with follow-upFrance2014-2014General population-1411012.7Rosso - 2016Case reportColombia2014-2014Dengue co-infection8.511100Balavoine - 2017Case seriesFrance2014-2015Neurologic10921315.4Epelboin - 2017Case reportFrance2014-2014General population611100Epelboin - 2017Case reportGuiana2014-2014General population1011100Evans-Gilbert - 2017Case reportJamaica2014-2014Neonatal422100Godaert - 2017Case seriesFrance2014-2014Geriatric58353859.1Sá - 2017Case seriesBrazil2016-2016General population1544100Cardona-Ospina - 2018Case reportColombia2018-2018Dengue/Leptospirosis co-infection-11100Colavita - 2018Case reportItaly2017-2017General population311100Dorleans - 2018Case seriesFrance2013-2015Hospitalized-7418364Gupta - 2018Observational with follow-upIndia2016-2016Critically ill-226036.7Koeltz - 2018Case seriesFrance2014-2015Critically ill-186428.1Melo - 2018Case seriesBrazilNA-NAPost-mortem-22605630Mercado - 2018Case seriesColombia2014-2015Post-mortem21313100Silva Junior - 2018Case seriesBrazil2016-2017Chronic kidney disease-3831779310.2Gohel - 2019Observational with follow-upIndia2016-2016Neurologic-31102.7Lima Neto - 2019Case seriesBrazil2016-2017General population15169800000.2Pinto - 2019Case seriesBrazil2016-2017Chronic kidney disease-269946660.3Rahman - 2019Case seriesBangladesh2017-2017General population-36900.4Ray - 2019Observational with follow-upIndia2016-2016General population-72133.3Silva Junior - 2019Observational with follow-upBrazil2016-2017General population-3831827310.2Simião - 2019Case seriesBrazil2016-2018General population15245464950.5[^3]

France (17), India (11), Brazil (7), and Colombia (7) were the countries with the most report. Of note, the majority of French reports came from the French ultramarine territories. ([Table 1](#t1){ref-type="table"}) The reported central tendency of time between disease onset and death ranged from 2 days to 150 days, with a non-weighted median of 6 days. ([Table 1](#t1){ref-type="table"}) None of the follow-up studies reported the time between disease onset and death. It seems that the time to death among the geriatric populations was usually higher than that of the general population and other special populations such as in the critically ill, pediatric, or in patients with neurological symptoms.

There were some reports of deaths among children under 12 years old, however, the central tendency of age among the decedents was 53 years old or higher, with a non-weighted median of 67, ranging up to 80 years old. The deaths seem to be equivalently distributed between males and females. Regarding the diagnostic tests, polymerase chain reaction (PCR) in blood samples was more common, reported 27 times, while serology was reported 16 times. In six reports, both blood tests were used. Other non-ordinary tests were also mentioned, mainly PCR and serological tests performed using cerebral-spinal fluid (CSF) samples. These were usually conducted in critically ill patients.

Information on clinical manifestations of fatal cases is very scarce. Fever, rash, and arthralgia are mentioned in approximately half of the reports, but the presence or absence of other clinical manifestations is ignored in 70.0% to 85.0% of the reports depending on the clinical finding. Among all the 2140 decedents, the most common clinical findings were fever (22.0%), arthralgia (15.7%), myalgia (10.7%), headache (8.2%), skin rash (5.7%), nausea/vomiting (5.3%), arthritis (4.3%), and bleeding (2.6%), while the remaining clinical findings were present in less than 1.0% of all decedents.

The authors mentioned organic dysfunction in 91.2% of the reports. Neurologic dysfunctions were the most mentioned (47.4%), followed by respiratory (43.9%) and cardiovascular (42.1%) dysfunctions. Hepatic, hematological, and renal dysfunctions were also mentioned in up to 31% of the reports. Neurological findings, when reported, were present in 9% to 100% of the deceased. ([Table 2](#t2){ref-type="table"}) Among all the 2140 decedents, assuming that dysfunctions were not present when not reported, the most common dysfunctions were cardiovascular (7.2%), respiratory (6.4%), neurological (5.4%), renal (4.2%), liver (3.0%), and hematological (1.3%) ([Table 2](#t2){ref-type="table"}).

TABLE 2:Number of reported clinical dysfunctions among the dead subjects.StudyNumber of deathsLiver (%)Respiratory (%)Hematological (%)Cardiovascular (%)Renal (%)Neurological (%)Sarkar - 19672\-\-\-\-\--Ramful - 20071\--1(100.0)\-\--Rampal - 20076-1(16.7)\-\--6(100.0)Renault - 2007203\-\-\-\-\--Ernould - 20082\-\--1(50.0)-1(50.0)Ganesan - 20081\-\-\-\--1(100.0)Lemant - 2008162(12.5)4(25.0)-3(18.8)-4(25.0)Robin - 20082\-\--2(100.0)-2(100.0)Economopoulou - 2009657(10.8)18(27.7)-22(33.8)3(4.6)6(9.2)Suryawanshi - 20093\--1(33.3)\--2(66.7)Tandale - 2009265(19.2)5(19.2)1(3.8)5(19.2)15(57.7)20(76.9)Tournebize - 20092\-\-\-\--2(100.0)Chua - 201011(100.0)1(100.0)1(100.0)1(100.0)1(100.0)-Kee - 20101-1(100.0)1(100.0)-1(100.0)-Sam - 20101-1(100.0)1(100.0)1(100.0)1(100.0)1(100.0)Gaüzère - 2011213(14.3)7(33.3)-7(33.3)1(4.8)3(14.3)Gurav - 20123\-\-\-\-\--Hertz - 20125\-\-\-\--1(20.0)Garcia - 20142-1(50.0)\--2(100.0)-Hoz - 201531(33.3)3(100.0)2(66.7)2(66.7)3(100.0)1(33.3)Shaikh - 20151\-\-\-\--1(100.0)Sharp - 201528\-\-\-\-\--Thiery - 201518\-\-\-\-\--Torres - 201533(100.0)3(100.0)2(66.7)3(100.0)3(100.0)-Viasus - 20151-1(100.0)1(100.0)1(100.0)1(100.0)-Betancur - 20161-1(100.0)1(100.0)1(100.0)1(100.0)-Carta - 20163\-\-\-\-\--Crosby - 201618\-\-\-\-\--Gérardin - 20167-1(14.3)-5(71.4)-7(100.0)López - 20162\-\-\-\-\--Méndez-Domínguez - 201611(100.0)1(100.0)1(100.0)1(100.0)1(100.0)1(100.0)Mercado - 20167\--5(71.4)1(14.3)3(42.9)-Perti - 201662(33.3)1(16.7)5(83.3)2(33.3)3(50.0)4(66.7)Rollé - 201614\-\--12(85.7)\--Rosso - 201611(100.0)1(100.0)1(100.0)1(100.0)1(100.0)1(100.0)Balavoine - 20172-2(100.0)\-\--2(100.0)Epelboin - 20171\--1(100.0)\--1(100.0)Evans-Gilbert - 20172-1(50.0)1(50.0)1(50.0)1(50.0)1(50.0)Godaert - 201735\-\-\-\-\--Sá - 20174-4(100.0)\-\--4(100.0)Gupta - 201822\-\-\-\-\--Koeltz - 201818\-\--2(11.1)\--Melo - 201822\-\-\-\-\--Mercado - 201813-6(46.2)-8(61.5)6(46.2)-Silva Junior - 201838319(5.0)\-\-\-\--Gohel - 20193\-\-\-\--3(100.0)Lima Neto - 2019169\-\-\-\-\--Pinto - 2019269\-\-\-\-\--Rahman - 20193-1(33.3)\-\--2(66.7)Ray - 20197\-\-\-\-\--Silva Junior - 2019383\-\-\-\-\--Simião - 2019245-29(11.8)-13(5.3)\--[^4]

Comorbidities such as hypertension, rheumatic conditions, hepatic conditions, or diabetes were also seldomly mentioned. However, the authors mentioned the exacerbation of previous comorbidities in 64.3% of the reports. When present, exacerbation of these previous conditions preceding death ranged from 32% to 100% of deaths within each report. ([Table 3](#t3){ref-type="table"}) Hypertension (6.9%) and diabetes (5.6%) were the most common comorbidities; nevertheless, liver disease, COPD, chronic kidney disease, heart disease, and myasthenia gravis were also mentioned as clinical events preceding death. ([Table 3](#t3){ref-type="table"}) Among all the 2140 decedents, the most common comorbidities, were diabetes or hypertension (5.6% and 6.9% respectively), while rheumatic and hepatic conditions were reported in less than 1% of the deceased ([Table 3](#t3){ref-type="table"}).

TABLE 3:Reports mentioning comorbidities (number and percentage) among the deceased subjects.StudyNumberDeath dueHypertensioRheumatiHepatopathDiabeteOtherof deathsto comorbiditn (%)c (%)y (%)s (%)(%)y (%)Renault - 200720340.4\-\-\-\--Lemant - 20081650.0\--1(6.2)5(31.2)COPDTandale - 20092638.4\-\-\-\--Tournebize - 2009250.0\-\-\--MyastheniaKee - 20101100.0\-\-\-\--Sam - 20101100.01(100.0)\-\--Cardiac FailureGaüzère - 20112138.0\-\-\--score IGSIIGurav - 20123100.01(33.3)\--1(33.3)Ischemic heart diseaseHertz - 2012580.0\-\--1(20.0)Pleural effusionHoz - 2015333.01(33.3)\-\--Benign prostatic hyperplasiaSharp - 20152832.115(53.6)\--11(39.3)Obesity; Sickle cell anemia; Chronic kidney disease; LeptospirosisViasus - 20151100.0\-\-\-\--Betancur - 20161100.0-1(100.0)\-\--López - 20162100.0\-\-\-\--Perti - 2016633.3\--1(16.7)\--Cardona-Ospina - 20181100.01(100.0)\-\--Chronic heart failure; Atrial fibrillation; Chronic venous disease; Right bundle branch blockColavita - 20181100.01(100.0)\-\--Ischemic heart disease; Chronic inferior limbs arteriopathy; Bilateral carotid atherosclerosis[^5]

The critical appraisal showed an acceptable risk of bias. Of course, it is very difficult to critically assess different study designs for the same purpose. Nevertheless, the dimensions with the most questionable or not acceptable risk of bias were the dimensions "clinical information" and "demographics" of the death cases. ([Figure 2](#f2){ref-type="fig"}A) This impression also appears in all tables as the absence of information. "Not applicable" also appears frequently in specific dimensions, for example, it does not make sense to evaluate consecutive inclusion or complete inclusion of a single case report. ([Figure 2](#f2){ref-type="fig"}B) Often, systematic reviews make sensitive analyses using only the low risk of bias studies. However, the synthesis was intended to be only descriptive as there was a considerable high degree of lack of data from original studies. The sensitivity analysis did not lead to any additional interpretation.

FIGURE 2:Original reports critical appraisal.

DISCUSSION
==========

The main results to be discussed are: (a) CHIK-F lethality in the general population is believed to be less than 1%; however it can be as high as 33% and, additionally, among the critically ill requiring life support, lethality can be as high as 48%; (b) data about the chain of clinical events that lead to death are scarce; (c) nevertheless, the currently available data suggest that age above 53 years old, primarily respiratory, cardiovascular, or neurological dysfunction, as well as decompensated comorbidities, are the main clinical events preceding death.

This review was not designed to estimate mortality rates, and according to the inclusion criteria, only reports with deaths were analyzed. This may overestimate the mortality, as reports aiming to estimate mortality, but not observing death, would never be considered in the analyses. Nevertheless, the CHIK-F mortality estimation remains a topic of discussion. Although it is believed that CHIK-F has a low lethality, there is evidence that deaths attributable to CHIK-F are underreported[@B65] ^-^ [@B67], and during CHIK-F epidemic periods, the excess of all-cause mortality in the general population may increase by 1%, or more than the expected mortality, especially in individuals belonging in the extreme age groups[@B68] ^-^ [@B74].

The CHIK-F intra-hospital lethality varies considerably, ranging from 4% to 29%[@B17] ^,^ [@B19] ^,^ [@B26] ^,^ [@B57] ^,^ [@B71]. Also, there is evidence pointing that the lethality in critically ill CHIK-F group of patients is higher than that in all critically ill patients in the intensive care units (ICU)[@B24] ^,^ [@B50], although this may be controversial when adjusting lethality for severity scores[@B24] ^,^ [@B36]. When compared to CHIK-F overall lethality, specific groups, such as advanced age and decompensated comorbidities, may have increased lethality[@B17], but again this is controversial when adjusting for the Acute Physiology and Chronic Health Evaluation (APACHE) II score (which age is one of its predictors)[@B49].

So far, there are very few studies adjusting for the effects of predictors of death. Nevertheless, there is a mix of data pointing to similar clinical features of disease severity observed in this review leading to hospitalization of CHIK-F cases. There is evidence pointing to a higher rate of hospitalization of CHIK-F patients when compared with the general population, and this is more evident in the extreme age groups[@B47] ^,^ [@B57] ^,^ [@B75], and with diabetes or hypertension[@B36] ^,^ [@B57]. Additionally, there is a clear trend of disease severity proportion being higher in older patients[@B17] ^,^ [@B38] ^,^ [@B53]. Also, there is evidence that subjects with a typical presentation are less likely to be hospitalized, and subjects with signs of bleeding, vomiting, leukopenia, severe arthralgia, with neurological findings, or in the extreme age groups are more likely to be hospitalized[@B57] ^,^ [@B75] ^,^ [@B76]. Although comorbidities and unusual CHIK-F presentation are more frequent as age increases, there seems to be a small effect of age on hospitalization even when adjusted for comorbidities[@B76]. Additionally, diabetes-specific mortality also increased during CHIK-F epidemic[@B77] as patients with CHIK-F and diabetes had a higher proportion of severe infection when compared with those without diabetes[@B19]. A similar interpretation is possible with systemic hypertension[@B17].

The more frequent observation of severe cases in the extreme age groups can be explained by the lack of maturity in the immune system in newborns and a gradual deterioration of the immune system in old age. This phenomenon compromises the host's ability to defend against infection[@B78].

There is evidence that CHIK-F patients admitted to ICU are younger than patients admitted to the general ICU for other reasons. Nevertheless, the average severity score *indice de gravité simplifié* (IGS II) is higher among CHIK-F patients[@B24]. Additionally, there were no lethality differences among different age groups of critically ill CHIK-F patients when adjusting for the IGS II severity[@B24], and the effect of age on lethality may be suppressed when adjusting for the APACHE II severity score[@B49]. However, older age may still be associated with death in hospitalized patients even when adjusting for comorbidities[@B19] ^,^ [@B63].

Predictors of death in a sample of elderly patients with up to seven days of fever at the time of hospital admission were estimated to be: sensorimotor deficit, confusion or delirium, concurrent cardiovascular disorders, concurrent respiratory infection, absence of musculoskeletal pain, history of alcoholism, and concurrent digestive symptoms. The strongest predictors of this multivariable analysis with this cohort in descending order are concurrent cardiovascular disorders, concurrent respiratory infection, and sensorimotor deficit[@B47]. The internal performance of this survival model was good. However, this research did not provide a tool for individual risk estimation and none of its results were validated in an independent sample. The main issue with this result is that it includes only the elderly, therefore, generalization to the overall population is limited as older age could not be assessed as a predictor. Another multivariable analysis conducted with secondary surveillance data at a Brazilian Northeastern state during an epidemic period included 383 deaths and identified the following predictors: older age (the strongest predictor), male sex, hypertension, diabetes, chronic kidney disease, leukopenia, and vomiting[@B63]. These predictors were very similar to the clinical features preceding death identified in this review.

There are case reports on septic shock exclusively related to CHIK-V[@B42] ^,^ [@B66] ^,^ [@B79], and case reports of very unusual presentations preceding death such as peritonitis and intestinal perforation, possibly also related to the use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)[@B17] ^,^ [@B80]. Also, population common characteristics, such as alcohol abuse, are reported as associated to CHIK-F mortality[@B17].

Despite that, the incidence of unusual clinical manifestation was estimated to be high[@B76] (24%), the incidence of neurological complications among CHIK-F patients is often estimated to be less than 1%[@B58] ^,^ [@B76] ^,^ [@B81]. Nevertheless, different from other clinical manifestations related to comorbidities, neurological findings seem to be directly attributed to CHIK-F infection[@B82]; therefore, the presence of a neurological finding could be a worrisome sign of potential lethality. Central nervous system disorders are much more frequent than peripheral manifestations[@B82]. The most common neurological manifestations in adults were estimated to be Guillain-Barré syndrome, 64.3%; meningoencephalitis, 24.1%; and acute demyelinating encephalomyelitis, 8.0%[@B81] while in children seizure was the most common[@B83]. Of course, other less frequent manifestations such as transverse myelitis and optic neuritis may be observed as well[@B79] ^,^ [@B81] ^,^ [@B82]. It seems that the illness duration up to the time of hospital admission is longer for subjects with neurological signs[@B62], and the time from infection to neurological manifestations and its lethality differ[@B81]. Guillain-Barré syndrome has the longest time to presentation and lowest lethality while meningoencephalitis has the shortest time to presentation and highest lethality[@B81]. Autopsy findings point to systemic involvement including encephalitis, hepatitis, myocarditis, and pulmonary edema[@B55], and it is possible that many patients with a neurologic clinical features do not have compatible findings at neurological imaging[@B16] ^,^ [@B83]. Nevertheless, cases indicating the potential benefits of passive immunization when encephalitis is present have been reported[@B84].

The limitations of this review are mainly related to scarcity and heterogeneity of original data on deceased subjects. The review included case reports, case-series, and cohort studies that are inherently prone to different sources of errors and misinterpretations and have different kinds of inherent design limitations. For instance, it is very difficult to give a comprehensive interpretation of lethality from case-series and case reports as all the subjects of the same population at risk of death may not be observed or the population may not even be accurately defined and the number of deaths is so low that estimates may be unacceptably inaccurate.

There are also limitations inherent to the interpretations of the causes of death. In this review, as there are very few studies in the literature estimating the effect of determinants of deaths among CHIK-F patients, the approach was similar to the death certificates approach. Once a death is reported, we attempted to identify the chain of clinical events leading to death. This is somehow different from the epidemiological approach of determinants or predictors where the risk of death given a condition is the main concern. It is very difficult to estimate death rates from case series or cohort studies among the general population because, at some point, subjects with disease progression will probably become hospitalized. Additionally, when a subject has several conditions, it is difficult to know which conditions are the main contributors to death, unless a study is designed for this purpose. For instance, when comorbidities are present, it is very difficult to accurately determine if CHIK-F presentation is severe because of presence or exacerbation of comorbidities, or alternatively if comorbidities decompensate due to severe CHIK-F. As there are several studies underreporting CHIK-F deaths, it may be that most physicians believe CHIK-F exacerbates underlying chronic conditions leading to death. This is particularly important while assessing CHIK-F mortality, as CHIK-V may often not be considered the main contributor to death.

In conclusion, data about specific events known to increase the risk of death is scarce and heterogeneous. The same holds for clinical events preceding CHIK-F deaths. Currently, extremes of age, mainly the elderly, cardiovascular, neurological, or respiratory dysfunctions, and decompensated comorbidities are the main clinical events preceding death. Additionally, the data point to primary dysfunctions, as the main clinical events preceding deaths, to be more frequent than exacerbation of comorbidities. The evidence supporting exacerbation of comorbidities preceding deaths is stronger regarding when comorbid systemic hypertension and diabetes are present, although other comorbidities may be contributing. It would be highly valuable for guidelines and recommendations to explicitly define alarming features in CHIK-F that increase the risk of death. This will help in justifying hospitalization or close monitoring. Future research aimed at the development or validation of clinical prediction tools will be of great use.
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